The current study is a continuation of our previous phase 2 investigation in mild–moderate AD patients treated with the DDR1 inhibitor, nilotinib, which significantly lowered CSF Aβ levels and amyloid burden as measured by PET [33]. The gene discussed is DDR1; the disease is Alzheimer disease.